Search
for
Did you mean JAK1/2 inhibitor?
Research 10 of 788
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Under Development JAK Inhibitors for Dermatologic Diseases
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →